Tag: Dermatomyositis
-

Priovant Wins FDA Approval for Lisraya in Dermatomyositis
The FDA approved Lisraya (brepocitinib), the first oral treatment option for adults with dermatomyositis, based on positive Phase 3 VALOR results.
-

Vyvgart Moves Into Autoimmune Muscle Disease After Phase 3 Win
Vyvgart Hytrulo met the primary endpoint in the Phase 3 ALKIVIA study, strengthening argenx’s case for expanding FcRn inhibition into autoimmune muscle disease.